Skip to main content
Premium Trial:

Request an Annual Quote

Keeps on Coming

Roche is letting 6 percent of its workforce, or about 4,800 people, go, reports Ed Silverman at Pharmalot. A Roche statement on its Operational Excellence Program says that 800 cuts will be to product development staff and 600 cuts to research and early development positions, while sales and marketing will bear the largest share of the cuts, with a loss of 2,650 positions. In addition, there will be reorganization to some technical operations. The cuts will take place over the next two years and is expected to save the company about $2.4 billion.

Our sister publication GenomeWeb Daily News has more here.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.